The long-term outcome of patients with polycystic liver disease treated with lanreotide

Autor: Chrispijn, M, Nevens, F, Gevers, TJG, Vanslembrouck, R, van Oijen, MGH, Coudyzer, W, Hoffmann, AL (Aswin), Dekker, HM, de Man, Rob, van Keimpema, L, Drenth, JPH

Publikováno v: Alimentary Pharmacology & Therapeutics, 35, 266-74
Alimentary Pharmacology & Therapeutics, 35, 2, pp. 266-74
Alimentary Pharmacology & Therapeutics, 35(2), 266-274. Wiley-Blackwell Publishing Ltd

Item does not contain fulltext BACKGROUND: Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycysti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e942dc38b56023501d7e162ff4970d04
http://hdl.handle.net/2066/109875